detect
respiratori
virus
convent
cultur
techniqu
still
consid
gold
standard
howev
result
mostli
avail
late
impact
patient
manag
latest
develop
includ
appropri
dnaand
rnabas
amplif
techniqu
nasba
pcr
detect
extend
number
agent
respons
lrti
real
time
amplif
latest
technic
progress
produc
within
consider
shorter
time
result
lower
risk
fals
posit
result
obtain
within
day
patient
manag
appropri
therapi
reduct
unnecessari
antibiot
therapi
lrti
possibl
number
technic
aspect
amplif
assay
advantag
discuss
avail
use
new
diagnost
tool
virolog
contribut
better
understand
role
respiratori
virus
lrti
increas
import
viral
agent
mycoplasma
pneumonia
chlamydophila
pneumonia
ari
illustr
great
proport
ari
caus
virus
rel
import
depend
spectrum
agent
cover
diagnost
techniqu
popul
studi
geograph
locat
season
discoveri
new
virus
ongo
exampl
hmpv
increas
number
coronavirus
indic
use
rapid
techniqu
differ
clinic
situat
discuss
depend
possibl
laboratori
could
optim
diagnost
strategi
appli
combin
immunofluoresc
detect
rsv
ifl
combin
realtim
amplif
test
respiratori
virus
atyp
agent
implement
strategi
compromis
sensit
clinic
util
turn
around
time
cost
found
present
still
great
deficit
etiolog
diagnosi
communityacquir
lower
respiratori
tract
infect
lrti
studi
case
remain
without
etiolog
diagnosi
result
unnecessari
inappropri
antibiot
prescrib
wide
varieti
diagnost
procedur
techniqu
appli
detect
etiolog
pathogen
communityacquir
lrti
tradit
diagnost
cultur
method
lack
sensit
feasabl
mani
context
focu
larg
number
aetiolog
agent
recent
year
consider
number
previous
unknown
respiratori
agent
discov
whose
vitro
cultur
slow
even
unreal
human
metapneumovirus
novel
coronavirus
human
bocaviru
new
polyomavirus
call
atyp
bacteri
caus
mycoplasma
pneumonia
chlamydophila
pneumonia
legionella
pneumophila
tradit
diagnost
method
also
insensitv
slow
produc
result
sever
day
therefor
altern
diagnost
procedur
develop
antigen
detect
latex
agglutin
immunofluoresc
dif
elisa
immunochromatographi
nucleic
acid
amplif
techniqu
naat
particularli
pcr
nasba
nucleic
acid
sequenc
base
amplif
past
two
decad
naat
revolution
diagnost
procedur
manag
patient
rti
result
combin
improv
sensit
specif
potenti
automat
product
rapid
result
naat
alreadi
becom
gold
standard
diagnost
field
assay
approv
us
food
drug
administr
fewer
still
enter
daili
routin
diagnosi
manag
patient
ascrib
rapid
evolut
technolog
cost
technolog
larg
number
etiolog
agent
bacteri
well
viral
respons
communityacquir
lrti
overview
therefor
provid
look
gener
principl
advantag
diagnost
valu
limit
current
use
amplif
techniqu
etiolog
diagnosi
respiratori
tract
infect
evolv
research
daili
practic
tabl
tradit
naat
involv
three
step
sampl
prepar
includ
extract
nucleic
acid
na
na
amplif
detectionidentif
amplicon
produc
pcr
first
still
common
frequent
appli
nucleic
acidbas
assay
mainli
procedur
wide
known
publish
altern
amplif
method
detect
pcr
amplicon
origin
reli
electrophoresi
presenc
ethidium
bromid
visual
result
band
uv
irradi
comparison
refer
product
identif
amplicon
howev
specif
hybrid
label
probe
time
consum
requir
multipl
pcr
product
handl
step
risk
spread
amplicon
throughout
laboratori
result
laboratori
contamin
fals
posit
result
subsequ
assay
altern
amplicon
may
captur
onto
solid
phase
detect
enzym
immunoassay
conveni
examin
clinic
sampl
batch
nasba
rna
amplifi
simultan
action
three
enzym
revers
transcriptas
also
polymeras
activ
rnase
rna
polymeras
synthesi
cdna
prime
special
design
oligonucleotid
primer
one
end
targetspecif
sequenc
contain
promot
rna
polymeras
revers
transcriptas
synthes
rnadna
hybrid
rnase
h
digest
rna
compon
revers
transcriptas
synthes
doubl
strand
dna
final
rna
polymeras
produc
numer
rna
copi
amplif
product
nasba
singl
strand
rna
detect
enzymelink
gel
assay
electroluminesc
ieven
loen
one
advantag
nasba
compar
pcr
continu
isotherm
process
requir
thermocycl
constant
temperatur
maintain
throughout
amplif
reaction
allow
step
reaction
proceed
soon
amplif
intermedi
becom
avail
addit
rna
genom
materi
numer
respiratori
virus
applic
rnabas
amplif
techniqu
offer
potenti
advantag
com
kidd
et
al
va
region
variabl
subgenera
rflp
morri
et
al
hexon
bp
subgenu
c
na
type
tiemessen
nel
longfib
gene
bp
subgenu
f
ah
avellon
et
al
hexon
bp
polyval
allard
et
al
hexon
type
narflp
rhinoviru
gamma
et
al
noncod
region
hyypia
et
al
noncod
region
h
arruda
hayden
noncod
region
johnston
et
al
noncod
region
bp
h
santti
et
al
noncod
region
bp
samuelson
et
al
noncod
region
nasba
ecl
andeweg
et
al
noncod
nah
steining
et
al
noncod
region
bp
na
billaud
et
al
noncod
region
rhino
v
na
loen
et
al
noncod
region
nasbaecl
deffernez
et
al
noncod
region
pare
dnabas
amplif
techniqu
addit
revers
transcriptas
step
requir
thu
save
time
reduc
risk
contamin
specif
reaction
might
howev
lower
enzym
use
thermost
reaction
temperatur
may
exceed
c
without
compromis
reaction
howev
specif
rate
increas
addit
hybrid
targetspecif
probe
ramirez
et
al
leg
pn
pn
c
pn
valassina
et
al
ifla
rsv
osiowi
rsv
pfl
ade
fan
et
al
ifla
b
rsv
pfl
echevarria
et
al
pfl
pitkaranta
et
al
rhi
rsv
cor
grondahl
et
al
ifla
b
rsv
pfl
ade
ev
pn
c
pn
corn
et
al
pfl
tong
et
al
improv
reproduc
inhous
develop
nasba
standard
reagent
nuclisen
basic
kit
commerci
avail
fox
et
al
contain
necessari
reagent
na
releas
inactiv
rnase
dnase
silica
extract
nucleic
acid
nasba
reagent
reagent
chemoluminesc
detect
includ
gener
ecl
probe
primer
target
specif
captur
probe
synthes
target
naat
avail
respiratori
agent
whenev
possibl
consensu
primer
abl
detect
virus
famili
genu
must
use
abil
amplifi
virus
effici
must
care
evalu
particularli
enteroand
rhinovirus
loen
et
al
judici
choic
primer
high
specif
naat
ascertain
refer
protocol
tradit
naat
present
tabl
tabl
present
either
earliest
public
diagnosi
particular
agent
assay
direct
altern
target
use
differ
method
agent
review
tabl
present
protocol
detect
variou
combin
etiolog
agent
convent
pcr
reaction
mention
tabl
amplicon
detect
done
agaros
gel
electrophoresi
without
hybrid
occasion
restrict
fragment
length
polymorph
enzym
immunoassay
viru
group
sever
protocol
propos
differ
target
chosen
amplicon
detect
techniqu
appli
differ
conveni
rsv
procedur
sensit
compar
cell
cultur
immunofluoresc
pcr
definit
sensit
adult
older
person
result
lower
viru
product
patient
landri
et
al
multipl
protocol
frequent
virusgroup
contain
multipl
virustyp
sever
amplif
protocol
develop
cover
particular
type
group
among
adenovirus
rhinoviru
type
close
relationship
enterovirus
constitut
special
challeng
judici
choic
primer
particularli
hybrid
probe
ensur
satisfactori
coverag
rhinoviru
type
illustr
loen
et
al
use
new
primer
rhinovirus
detect
five
time
frequent
clinic
sampl
tradit
cultur
techniqu
two
elden
et
al
n
gene
type
b
taqman
mentel
et
al
f
gene
taqman
gueudin
et
al
n
gene
light
cycler
borg
et
al
f
gene
taqman
kuyper
et
al
matrix
protein
gene
taqman
shea
cane
n
gene
amplitaq
perkin
et
al
f
n
gene
type
b
ab
prism
human
metapneumoviru
cote
et
al
n
gene
light
cycler
mackay
et
al
n
gene
light
cycler
maertzdorf
et
al
n
gene
abi
prism
three
time
studi
use
previous
describ
primer
studi
compar
two
differ
molecular
amplif
techniqu
appli
consider
number
clinic
specimen
rare
facetofac
comparison
two
amplif
protocol
done
sarscoronaviru
yam
et
al
nasba
revers
transcriptas
pcr
advantag
recent
studi
loen
et
al
compar
nasba
pcr
nasopharyng
aspir
collect
children
present
acut
respiratori
tract
infect
univers
hospit
antwerp
nasba
revers
transcriptas
pcr
produc
compar
result
significantli
sensit
viru
cultur
protocol
legionella
spp
develop
detect
singl
type
clinic
specimen
mutipl
speci
environment
water
overview
literatur
use
naat
detect
pneumonia
sinc
given
review
loen
et
al
descript
current
avail
molecular
amplif
method
topic
discuss
includ
specimen
collect
transport
prepar
nucleic
acid
clinic
specimen
choic
target
sequenc
detect
amplicon
method
recogn
prevent
fals
posit
fals
neg
result
result
naat
comparison
result
obtain
convent
diagnost
test
clinic
applic
also
review
review
diagnosi
c
pneumonia
kumar
hammerschlag
conclud
studi
naat
respiratori
specimen
reveal
signific
variat
test
perform
laboratori
laboratori
await
valid
standard
multiplex
pcr
sever
independ
amplif
carri
simultan
one
tube
mixtur
primer
multiplex
naat
develop
detect
microorgan
simultan
instanc
two
separ
assay
tabl
indic
increas
number
target
one
reaction
result
loss
sensit
tong
et
al
vernet
tong
choi
et
al
four
multiplex
one
monoreact
abbrevi
see
tabl
observ
lower
sensit
log
pneumonia
chlamydia
pneumonia
compar
individu
pcr
respiratori
sampl
sensit
multiplex
assay
pneumonia
c
pneumonia
chlamydia
psittaci
respect
vernet
observ
analyt
sensit
multiplex
rtpcr
detect
six
virus
ie
influenza
influenza
b
rsv
ab
parainfluenza
reduc
factor
log
compar
singl
detect
depend
viru
nevertheless
multiplex
assay
abl
identifi
correctli
infect
respiratori
specimen
decreas
sensit
unexpect
sinc
presenc
sever
pair
primer
may
increas
probabl
mispair
result
nonspecif
amplif
product
format
primerdim
furthermor
enzym
primer
salt
concentr
well
temperatur
cycl
requir
target
may
slightli
differ
one
assay
commerci
avail
pneumoplex
prodess
milwauke
usa
target
seven
respiratori
virus
includ
qualiti
control
exercis
although
limit
detect
assay
report
cfuml
pneumonia
tcid
ml
c
pneumonia
copi
recombin
dna
organ
khanna
et
al
test
perform
well
evalu
loen
et
al
manufactur
contact
awar
sensit
problem
pneumoplex
assay
intend
improv
sensit
assay
commerci
avail
multiplex
test
hexaplex
test
still
technic
demand
requir
h
handsontim
hindiyeh
et
al
differ
approach
appli
coira
et
al
sampl
submit
two
multiplex
transcript
pcr
assay
follow
reverselin
blot
assay
detectionidentif
group
virus
procedur
howev
also
take
time
latest
evolut
combin
convent
pcr
microarray
detect
recent
describ
li
et
al
evalu
posit
two
commerci
multiplex
panel
ngen
resplex
ii
detect
respiratori
virus
virusgroup
respect
microarray
luminex
liquid
chip
hybrid
identif
respect
sensit
two
assay
also
lower
monoplex
realtim
revers
transcriptas
pcr
assay
notic
rsv
although
might
improverd
primerprob
optim
chang
primerprob
sequenc
could
neg
influenc
assay
target
multiplex
reaction
although
handsontim
test
approxim
min
turnaround
time
still
h
resplex
ii
h
ngen
base
principl
eight
distinct
viru
group
differ
respiratori
virus
amplifi
multiplex
reaction
lee
et
al
mahoni
et
al
respect
amplicon
detect
fluid
microspherebas
array
univers
array
tm
bioscienc
luminex
xmap
system
techniqu
therefor
competit
mani
case
gradual
replac
realtim
multiplex
reaction
greater
user
friendli
singl
target
realtim
naat
tabl
combin
use
capillari
glass
tube
heat
air
shorten
significantli
cycl
time
togeth
use
fluorogen
probe
allow
onlin
fluoresc
detect
amplif
result
consider
increas
speed
rtpcr
sinc
amplif
detect
perform
simultan
seal
tube
need
manipul
elimin
risk
carryov
contamin
probe
simplest
chemistri
use
sybr
green
dye
bind
ds
dna
gener
pcr
howev
lower
specif
due
unspecif
bind
ds
dna
altern
taqman
probe
molecular
beacon
quencher
molecul
remov
vicin
fluoresc
marker
probe
upon
bind
rna
dna
gener
amplif
call
fret
technolog
two
probe
one
fluoresc
donor
one
fluoresc
acceptor
molecul
design
bind
adjac
sequenc
amplicon
gener
signal
rt
detect
molecular
beacon
also
applic
nasba
ieven
loen
loen
et
al
rna
virus
preliminari
synthesi
cdna
origin
done
separ
tube
done
singl
tube
togeth
amplificationdetect
tradit
naat
gradual
replac
realtim
format
target
may
use
sensit
specif
rtpcr
ident
convent
pcr
l
pneumophila
hayden
et
al
pneumonia
templeton
et
al
ursi
et
al
well
rsv
mentel
et
al
studi
superior
sensit
rtpcr
versu
convent
pcr
mention
agent
rhinovirus
dagher
et
al
sarscoronaviru
comparison
differ
rtpcr
sarscoronaviru
show
signific
differ
sensit
specif
chui
et
al
hourfar
et
al
mahoni
et
al
number
agent
detect
simultan
one
rt
reaction
tube
restrict
number
avail
wavelength
exist
equip
mostli
three
present
sever
reaction
tube
run
parallel
major
drawback
approach
reduct
amount
na
introduc
amplif
higher
handsontim
requir
manipul
tube
thermocycl
may
suboptim
agent
involv
assay
simultan
assay
compromis
made
optim
temperatur
cycl
requir
sensit
compon
rt
multiplex
pcr
appli
two
three
agent
simultan
mostli
influenza
b
togeth
rsv
one
first
multiplex
pcr
develop
welti
et
al
pcr
done
two
separ
reaction
first
reaction
pneumonia
c
pneumonia
detect
second
reaction
l
pneumophila
togeth
commerci
intern
control
ipl
appli
biosystem
rt
multiplex
nasba
diagnosi
pneumonia
c
pneumonia
l
pneumophila
develop
loen
et
al
multiplex
nasba
perform
one
tube
group
compar
multiplex
assay
correspond
monoassay
sensit
multiplex
pcr
ident
convent
pcr
multiplex
nasba
assay
less
sensit
compar
correspond
rt
mono
nasba
procedur
loss
sensit
also
mention
tong
et
al
convent
multiplex
pcr
agent
mention
templeton
et
al
develop
twotub
rt
multiplex
pcr
diagnosi
influenza
b
rsv
first
tube
four
parainfluenzavirus
second
tube
sensit
higher
cultur
dif
test
comparison
made
multiplex
reaction
monoreact
sampl
grutek
et
al
appli
four
multiplex
reaction
detect
agent
templeton
et
al
cover
agent
six
multiplex
realtim
reaction
gunson
et
al
target
agent
four
realtim
multiplex
reaction
research
need
identifi
reaction
combin
minim
loss
sensit
rt
naat
cycl
threshold
ct
relat
quantiti
viru
present
sampl
provid
sampl
standard
comparison
ct
valu
allow
rel
quantif
viral
load
use
follow
evolut
infect
particular
patient
absolut
quantif
sever
standard
use
past
high
titer
viru
prepar
tissu
cultur
quantifi
bacteri
suspens
viru
suspens
quantifi
electron
microscopi
popular
inhous
clone
plasmid
dna
measur
correspond
number
target
molecul
calcul
construct
standard
curv
fronhoff
et
al
allow
absolut
quantif
express
number
viral
particl
vijgen
et
al
still
lack
inform
signific
viral
load
respiratori
infect
higher
amount
rsv
found
children
less
month
age
far
quantit
studi
go
higher
viral
load
correspond
sever
clinic
diseas
quantit
data
differenti
colon
infect
lack
entir
devincenzo
et
al
molecular
diagnosi
respiratori
infect
prefer
clinic
specimen
nasopharyng
aspir
npa
sputum
covalciuc
et
al
well
bronchoalveolar
lavag
specimen
avail
superior
npa
detect
virus
clearli
illustr
studi
grutek
et
al
percentag
diagnos
episod
npa
compar
swab
avail
nasal
swab
suit
detect
rsv
studi
heikkinen
et
al
copan
flock
swab
univers
transport
medium
collect
transport
system
univers
system
compat
antigen
kit
dfa
cultur
pcr
castriciano
et
al
castriciano
et
al
daley
et
al
nasal
swab
newflock
swab
equival
tradit
rayon
nasopharyng
swab
np
less
patient
discomfort
significantli
epitheli
cell
collect
flock
swab
provid
better
specimen
diagnosi
furthermor
np
collect
flock
swab
detect
higher
number
posit
np
collect
dacron
swab
specimen
intend
nasba
revers
transcript
pcr
introduc
immedi
collect
appropri
buffer
maintain
rna
integr
isol
purif
na
laborintens
part
molecular
diagnost
test
na
extract
origin
perform
phenolchloroform
wide
replac
boom
method
boom
et
al
commerci
sampl
prepar
kit
method
time
consum
labor
intens
suscept
contamin
especi
detect
l
pneumophila
contamin
problem
describ
use
filterscolumn
flush
water
prepar
shown
potenti
contamin
nonpneumophila
legionella
spp
evan
et
al
van
der
zee
et
al
b
probabl
fals
posit
result
contamin
increas
number
manipul
involv
sampl
process
late
complet
automat
introduc
perform
rna
well
dna
extract
within
min
small
high
number
specimen
although
robot
autom
sampl
prepar
shown
perform
equal
consist
manual
techniqu
limit
number
studi
avail
varieti
respiratori
specimen
studi
l
pneumophila
pneumonia
c
pneumonia
respiratori
specimen
sever
author
show
perform
autom
magnapur
nuclisen
extract
procedur
easymag
minimag
superior
compar
manual
extract
method
loen
et
al
wilson
et
al
reaction
exclus
direct
dna
virus
adenovirus
herp
virus
simpl
heat
throat
swab
extract
feasibl
faix
et
al
appli
pneumonia
ieven
et
al
multiplex
reaction
direct
adenoviru
pneumonia
c
pneumonia
l
pneumophila
simpl
heat
sampl
might
explor
suitabl
control
monitor
na
extract
amplif
procedur
well
qualiti
specimen
detect
laboratori
contamin
control
present
alway
includ
test
panel
posit
control
assur
correct
amplif
taken
place
intern
control
ad
sampl
na
extract
monitor
effici
extract
detect
inhibitor
possibl
laboratori
contamin
neg
result
may
point
absenc
target
organ
sampl
presenc
low
copi
number
presenc
amplif
inhibitor
poor
qualiti
specimen
differ
type
intern
control
ic
avail
loen
et
al
homolog
extrins
control
amplicon
modifi
nontargetderiv
sequenc
insert
ad
sampl
prior
na
extract
coamplifi
primer
use
target
ursi
et
al
ursi
et
al
allow
monitor
precis
combin
effect
extract
amplif
quantiti
ic
ad
low
prevent
competit
real
target
homolog
extrins
control
construct
amplif
target
separ
heterolog
extrins
control
dna
rna
deriv
virus
infect
human
seal
herp
viru
phocin
distemp
viru
propos
niester
niester
noncompetit
ad
amplif
reaction
requir
addit
specif
primer
dingl
et
al
propos
modifi
hepat
deltaviru
purpos
final
heterolog
intrins
control
certifi
presenc
human
na
thu
possibl
viru
contain
cellular
materi
sampl
exampl
betaglobin
gamma
interferon
dehydrogenas
gene
loen
et
al
particularli
import
throat
swab
specimen
may
inadequ
scrape
mucos
surfac
sputum
specimen
may
contain
leucocyt
apfalt
et
al
discuss
step
naat
procedur
need
proper
attent
preanalyt
procedur
assay
design
interpret
result
qualiti
control
use
intern
control
mandatori
assur
human
na
present
sampl
highli
recommend
synthesi
primer
probe
genom
evolut
geograph
genom
divers
taken
account
particularli
rna
virus
matrix
posit
control
whether
whole
viru
nucleic
acid
natur
clinic
sampl
tradit
cultur
techniqu
compar
naat
latter
gener
detect
consider
posit
specimen
small
number
cultur
posit
miss
naat
except
naat
alway
sensit
cultur
dif
antigen
detect
procedur
henrickson
henrickson
jen
et
al
murdoch
numer
inhous
pcr
assay
detect
atyp
develop
case
mani
viral
assay
well
proper
valid
standard
often
lack
valid
must
perform
sever
level
includ
sampl
prepar
amplif
detect
conclud
standard
workshop
c
pneumonia
assay
dowel
et
al
conclus
work
group
studi
need
conduct
use
proper
control
larg
number
clinic
specimen
compar
evalu
adequ
use
differ
pcr
test
diagnosi
c
pneumonia
infect
instanc
posit
neg
predict
valu
naat
calcul
ppv
npv
naat
rhinovirus
compar
cultur
respect
loen
et
al
two
adenoviru
naat
vabret
et
al
found
ppv
npv
respect
gueudin
et
al
regist
ppv
npv
rsv
naat
compar
cultur
respect
absenc
gold
standard
requir
adapt
statist
techniqu
evalu
properli
differ
diagnost
techniqu
especi
sensit
naat
hadgu
et
al
nevertheless
molecular
techniqu
gradual
replac
tissu
cultur
gold
standard
diagnosi
respiratori
infect
arden
et
al
kuyper
et
al
murdoch
templeton
et
al
van
de
pol
et
al
van
elden
et
al
inlaboratori
develop
test
verifi
analyt
clinic
perform
illustr
number
studi
need
standard
materi
particularli
quantit
test
particip
extern
qualiti
control
program
commerci
kit
hardli
avail
respiratori
agent
except
sarscoronaviru
rtpcr
situat
may
evolv
rapidli
researchuseonli
kit
alreadi
avail
c
pneumonia
cherneski
et
al
well
standard
reagent
kit
intern
control
ipl
apli
biosystem
commerci
multiplex
test
convent
pneumoplex
hexaplex
prodess
idtag
respiratori
viral
panel
tm
bioscienc
corp
toronto
canada
real
time
format
chlamyleg
argen
ginevra
et
al
greatest
problem
overcom
molecular
method
fals
posit
caus
contamin
although
automat
sampl
prepar
real
time
naat
repres
signific
progress
matter
fals
neg
associ
great
differ
sensit
home
made
assay
apfalt
et
al
loen
et
al
templeton
et
al
van
vliet
et
al
task
qc
taken
intern
collabor
laboratori
qcmd
qualiti
control
molecular
diagnost
endors
european
societi
clinic
virolog
escv
european
societi
clinic
microbiolog
infecti
diseas
evalu
use
naat
diagnosi
acut
respiratori
infect
object
etiolog
diagnosi
condit
rememb
avoid
empir
start
antibiot
treatment
allow
narrow
spectrum
target
antibiot
treatment
allow
appropri
use
antivir
drug
allow
cohort
patient
case
hospit
prevent
nosocomi
spread
provid
accur
epidemiolog
inform
formul
prevent
therapeut
recommend
decreas
durat
hospit
stay
reduc
manag
cost
answer
first
three
object
diagnosi
avail
rapidli
prefer
within
h
tradit
naat
unabl
fulfil
requir
recent
technic
progress
brought
naat
age
develop
kinet
realtim
rt
test
coupl
automat
na
extract
multitud
report
appear
epidemiolog
ari
restrict
virus
influenza
sometim
togeth
rsv
rhino
metapneumoor
coronavirus
andor
popul
group
eg
children
adult
old
age
peopl
great
variat
occur
function
time
place
age
group
studi
esper
et
al
guittet
et
al
mcadam
et
al
monto
tsolia
et
al
appear
rsv
common
caus
viral
ltri
young
children
drummond
et
al
freymuth
et
al
ieven
et
al
increas
import
rhinovirus
young
children
miller
et
al
rsv
rhinoand
influenzavirus
common
older
peopl
falsey
walsh
nicholson
et
al
coronavirus
pneumonia
also
preval
previous
thought
billaud
et
al
loen
et
al
wait
talkington
time
progress
import
recent
discov
human
bocaviru
alland
et
al
kesebir
et
al
klein
et
al
kupfer
et
al
mcintosh
human
metapneumoviru
infect
boivin
et
al
dare
et
al
orda
et
al
van
den
hoogen
coronavirus
koetz
et
al
vabret
et
al
becom
evid
although
role
new
virus
becom
clear
specif
patient
popul
studi
need
identifi
clinic
relev
other
bocaviru
tradit
naat
requir
least
day
therefor
former
studi
done
posteriori
ie
result
avail
clinician
time
possibl
impact
patient
manag
cover
wide
spectrum
etiolog
respiratori
agent
number
uniandor
multiplex
reaction
perform
simultan
combin
tradit
bacteriolog
techniqu
diagnos
streptococcu
pneumonia
infect
infect
remain
etiolog
undefin
multiplex
studi
templeton
et
al
studi
grutek
et
al
studi
limit
time
pilot
trial
wider
applic
multiplex
reaction
recent
year
also
result
detect
numer
simultan
viral
infect
wide
vari
incid
guittet
et
al
bellaupujol
et
al
latter
studi
bacteri
agent
also
includ
differ
incid
may
result
varieti
diagnost
panel
appli
preferenti
combin
virus
studi
found
combin
infect
associ
sever
clinic
statu
sempl
found
sever
bronchiol
associ
combin
hmpv
rsv
sempl
et
al
templeton
et
al
found
significantli
mix
infect
involv
also
bacteria
patient
sever
pneumonia
clinic
signific
combin
infect
remain
clarifi
respiratori
virus
also
increasingli
recogn
caus
sever
lower
respiratori
tract
infect
immunocompromis
host
ljungman
van
elden
et
al
whimbey
et
al
watzing
et
al
respiratori
infect
common
solid
organ
recipi
particularli
lung
transplant
recipi
kotloff
et
al
infect
especi
danger
prior
engraft
month
transplant
set
graft
versu
host
diseas
origin
infect
communityacquir
well
nosocomi
barron
weinberg
epidemiolog
inform
role
panel
respiratori
viral
pathogen
becom
avail
clear
screen
virus
specif
patient
popul
transplant
patient
young
children
elderli
desir
prevent
therapeut
recommend
may
take
inform
account
avail
sensit
naat
recent
year
also
put
oftenus
serolog
test
right
perspect
reliabl
serolog
evid
ongo
infect
fourfold
rise
seroconvers
igg
antibodi
ill
therefor
pair
sampl
collect
interv
week
requir
practic
howev
often
one
serum
sampl
acutephas
ill
avail
two
sampl
collect
within
short
time
interv
detect
titr
rise
sinc
igm
antibodi
appear
earlier
igg
antibodi
detect
igm
serum
wide
use
approach
earli
serolog
diagnosi
mani
acut
infect
realiz
igm
antibodi
often
produc
children
month
age
proport
primari
infect
reinfect
igm
respons
may
also
appear
late
solitari
high
igg
titer
diagnost
mean
acut
infect
sinc
moment
seroconvers
unknown
necessarili
took
place
time
ill
observ
start
singl
high
titr
cutoff
valu
determin
local
evalu
use
preval
studi
among
popul
group
clinic
signific
serolog
test
igm
igg
defin
studi
patient
document
infect
detail
inform
concern
time
laps
onset
diseas
collect
serum
specimen
known
rothbarth
detect
fourfold
igg
antibodi
rise
eia
patient
day
influenza
infect
rothbarth
et
al
rsv
medden
et
al
found
signific
increas
igg
antibodi
eia
patient
studi
day
onset
diseas
serolog
test
respiratori
infect
usual
lack
specif
nirpaz
et
al
petitjean
et
al
mani
test
format
pneumonia
propos
sever
studi
illustr
lack
standard
antigen
pneumonia
talkington
et
al
one
studi
pcrdocument
pneumonia
infect
diagnos
acut
convalesc
phase
sera
respect
anoth
studi
anti
pneumonia
igm
antibodi
detect
depend
test
appli
acut
sera
igg
antibodi
convalesc
sera
depend
time
second
sampl
studi
illustr
low
incid
igm
antibodi
acut
phase
serum
specimen
import
delay
two
serum
sampl
legionella
antibodi
test
sensit
depend
assay
appli
also
substanti
improv
diagnosi
legionellosi
yzerman
et
al
serolog
test
never
offer
earli
diagnosi
therefor
rather
epidemiolog
diagnost
tool
armamentarium
avail
howev
hard
conceiv
everi
hospit
laboratori
would
perform
broad
spectrum
rt
naat
even
standard
reagent
low
cost
becom
wide
avail
strategi
develop
adapt
evolut
technolog
naat
popul
patient
serv
children
elderli
immunocompromis
patient
resourc
avail
infrastructur
staff
fulltim
servic
servic
limit
hour
day
day
week
number
natur
agent
cover
perman
consult
laboratorian
clinician
becom
necessari
ever
nolt
propos
consid
three
level
servic
provid
clinic
laboratori
level
perform
fda
approv
test
level
perform
fda
approv
researchuseonli
test
protocol
adequ
approv
laboratori
level
design
develop
verifi
inhous
test
howev
laboratori
belong
level
time
continu
reli
applic
viral
cultur
immunofluores
immunochromatograph
test
recogn
inher
lower
sensit
test
appli
certain
specimen
patient
viral
cultur
prerequisit
studi
viral
isol
particularli
import
influenzaviru
altern
cover
public
health
need
refer
laboratori
function
close
contact
inand
outpati
clinic
group
gener
practition
could
appli
broad
spectrum
diagnost
panel
group
patient
produc
requir
global
epidemiolog
inform
refer
laboratori
make
result
avail
daili
basi
region
local
laboratori
might
limit
investig
antibiot
treatabl
bacteri
infect
import
viral
infect
influenza
rsv
avoid
unnecessari
antibiot
treatment
communityacquir
bacteri
pneumonia
gram
stain
sputum
specimen
remain
fundament
rapid
low
cost
diagnost
procedur
could
combin
first
approach
multiplex
naat
diagnosi
slowli
grow
antibiot
sensit
bacteria
pneumonia
c
pneumonia
l
pneumophila
bordetella
pertussi
posit
result
may
lead
adapt
antibiot
therapi
result
neg
test
viral
caus
may
initi
although
present
clinician
stop
antibiot
patient
neg
bacteri
caus
falsey
propos
differ
protocol
summer
winter
month
summer
month
pcr
viral
test
perform
case
sever
ill
winter
month
strategi
differ
whether
influenza
epidem
ongo
falsey
et
al
sinc
region
import
ari
viral
agent
activ
mostli
winter
month
diagnost
procedur
detect
eg
influenza
rsv
could
limit
novemb
march
presenc
influenza
epidem
effort
could
entir
concentr
transfer
local
isol
refer
laboratori
subtyp
summer
month
pcr
viral
test
could
perform
specif
patient
popul
case
sever
ill
thoroughli
investig
specimen
infect
remain
without
known
infecti
caus
store
studi
aim
discoveri
yet
unidentifi
pathogen
inde
studi
etiolog
spectrum
ari
leav
consider
proport
case
without
known
caus
although
studi
grutek
et
al
templeton
et
al
fraction
reduc
respect
sinc
organ
discov
recent
multipli
poorli
tissu
cultur
may
surmis
agent
remain
discov
also
grow
poorli
tissu
cultur
illustr
recent
discoveri
previous
unknown
coronavirus
yam
et
al
human
metapneumoviru
maertzdorf
et
al
van
den
hoogen
et
al
bocaviru
alland
et
al
new
polyomavirus
alland
et
al
gaynor
et
al
studi
lead
discoveri
hidden
causal
agent
naat
alway
requir
everi
purpos
cohort
rsvinfect
pediatr
patient
dif
test
provid
result
within
min
chromatograph
test
produc
result
within
min
sensit
rsv
reina
et
al
ohmsmith
et
al
avail
done
laboratori
outsid
virolog
laboratori
work
hour
cazacu
et
al
test
howev
lack
sensit
appli
respiratori
sampl
adult
patient
landri
et
al
practic
issu
laboratori
may
limit
theoret
possibl
rapid
naat
necess
handl
specimen
batch
therebi
lose
advantag
rapid
test
moreov
virolog
laboratori
present
oper
h
day
situat
may
chang
molecular
test
may
requir
emerg
also
outsid
field
infecti
diseas
clinic
laboratori
therefor
also
integr
among
activ
naat
appli
field
respiratori
infect
arbovirus
emerg
test
meningoencephalitit
intrapartum
detect
streptococcu
agalactia
test
might
perform
perman
function
greatli
autom
laboratori
section
might
includ
molecular
diagnosi
preval
virus
moment
respiratori
infect
suscept
antibiot
amplif
techniqu
higher
cost
improv
sensit
rapid
result
lead
better
streamlin
therapi
decreas
antibiot
use
present
amplif
techniqu
expens
convent
approach
expens
fluorogenicbas
realtim
detect
system
technic
side
improv
standard
autom
widespread
use
result
cost
reduct
rate
competit
convent
method
addit
assess
overal
benefit
amplif
techniqu
direct
cost
pcr
reagent
equip
taken
consider
also
indirect
cost
save
decreas
antibiot
use
decreas
hospit
stay
remain
studi
sever
studi
mainli
base
antigen
test
tend
alreadi
show
cost
effici
rapid
diagnosi
ari
result
reduc
antibiot
use
complementari
laboratori
investig
significantli
shorter
hospit
reduc
isol
period
patient
barenfang
et
al
falsey
et
al
hueston
benich
rochol
et
al
welti
et
al
woo
et
al
oosterheert
et
al
point
lack
cost
reduct
avail
studi
result
small
impact
microbiolog
investig
therapeut
decis
epidem
may
also
import
rule
certain
infect
import
save
diagnost
procedur
possibl
abolish
tissu
cultur
serolog
test
ari
addit
improv
diagnost
without
educ
aspect
illustr
high
frequenc
rhinovirus
bronchiol
grutek
et
al
closer
collabor
clinician
laboratori
high
prioriti
number
aspect
remain
investig
implement
quantit
test
could
shed
light
relat
viru
load
serious
diseas
adachi
et
al
produc
use
prognost
inform
help
differenti
colon
infect
inform
could
gather
length
postinfect
carrier
state
well
import
subclin
infect
prone
spread
infect
import
ari
virus
chronic
respiratori
diseas
copd
cystic
fribrosi
could
also
better
evalu
sever
agent
respons
respiratori
infect
consid
separ
specif
clinic
pictur
respons
c
psittaci
b
pertusssi
b
parapertussi
coxiella
burnetii
pneumocysti
jeroveci
rapid
molecular
character
previous
unknown
sarscoronaviru
within
week
appear
diseas
discoveri
bocaviru
illustr
potenc
naat
broaden
knowledg
hidden
virus
remain
discov
furthermor
organiz
framework
diagnost
laboratori
naat
panel
direct
clinic
syndrom
meningoenceph
sepsi
sexual
transmiss
diseas
hepat
other
includ
near
futur
naat
probabl
done
point
care
must
remain
object
develop
technolog
need
detect
everexpand
number
infecti
agent
exceed
possiblit
mix
rtnaat
task
taken
next
gener
diagnost
array
technolog
open
wide
access
infecti
agent
ambros
clenli
lin
et
al
wang
et
al
mahoni
et
al
